new york, July 18, 2023 /PRNewswire/ — SYBLEU INC (OTC PINK: SYBE ), a biotechnology company focused on human and animal health, medical devices and clinical diagnostics, is preparing to begin developing novel small molecule drugs for animal and human health. Licensed AI/ML technology combined with small molecule patents.
Using AI/ML (Artificial Intelligence/Machine Learning) to screen for highly optimized small molecules that target specific receptors is a promising field that can greatly accelerate drug discovery and development. A recent article in the journal Nature Medicine (https://doi.org/10.1038/s41591-023-02361-0) describes the current state of the field.
Only six companies are listed as having drugs in clinical trials designed using AI/MI. Very recently, one of these companies, Recursion, announced $50 million Investment by NVIDIA (https://ir.recursion.com/news-releases/news-release-details/recursion-announces-collaboration-and-50-million-investment). Repetition itself has recently passed $87.5 million Acquisition of two AI/ML drug discovery companies (https://ir.recursion.com/news-releases/news-release-details/recursion-enters-agreements-acquire-cyclica-and-valence-bolster).
Dr. Harry LanderCyBlue’s Chief Scientific Officer. “We expect it will add significant value to the company as a scientific and strategic asset.”
“The field is very dynamic right now and consolidation is happening – this is normal when new technology is introduced that has the potential to change the situation,” he said. Joseph VineyCEO of Siblu.
About Sybleu Inc.
SYBLEU INC (OTC PINK: SYBE) is a biotechnology company focused on human and animal health, medical devices and clinical diagnostics. Our strategy is to acquire intellectual property and create strategic partnerships to bring technologies to market. SYBLEU Inc. He is currently exploring opportunities in veterinary medicine, diagnostics and medical devices. More information on SYBLEU is available at http://www.sybleu.com.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results may differ materially from those expressed, projected or implied in the forward-looking statements. Risks and uncertainties affecting forward-looking statements include the effects of government regulation, competition and other material risks.
Contact Address:
To Mr. Joseph G. Viney
Chairman and CEO
+ 1.800.807.4631 Tel
Email: [email protected]Sable.Com
Source: Sybleu Inc.
[ad_2]